Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558373 | 0.76 | ALDH1A1 (0.36) | ALDH1A1CYP1A2CYP3A4CYP2C19GAA | |
| SCHEMBL15690945 | 0.75 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1882995 | 0.69 | CYP2D6 (0.39) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL154558 | 0.64 | — | — | |
| SCHEMBL14421513 | 0.63 | LMNA (0.47) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| Iodide SCHEMBL11384035 | 0.62 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| Bromide SCHEMBL27881053 | 0.62 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9075652 | 0.62 | SNCA (0.40) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9075656 | 0.60 | LOXL2 (0.50) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7092048 | 0.59 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| US-6417202-B1 | 3-ACETYL-4-METHYL-2,5-DI(4-PYRIDYL)-1H-PYRROLE, FOR EXAMPLE; TREATING CELL ADHESION MOLECULES (CAMS) MEDIATED DISEASES SUCH AS ARTHRITIS, AIDS, SEPTIC SHOCK, CACHEXIA, TRANSPLANT REJECTION | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-20020022729-A1 | Pyridylfuran and pyridylthiophene compounds | KAWAI AKIYOSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| EP-0853083-B1 | Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6048880-A | THERAPY FOR CYTOKINE SENSITIVE DISEASES | PFIZER PHARAMACEUTICALS INC. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0912548-A1 | PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN- AND TNF ANTAGONISTS | PFIZER INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0853083-A1 | Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof | PFIZER INC. (US) | 1998-07-15 | — | — | EP | disclosed |
| WO-1998002430-A1 | PYRIDYLPYRROLE COMPOUNDS USEFUL AS INTERLEUKIN- AND TNF ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, FCGR2A, OGFR | SMN1; SMN2 3438/4885ALDH1A1 789/4885CYP1A2 1503/4885 |
| US-20020022729-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, CRHR1, NR3C2 | SMN1; SMN2 3340/4885ALDH1A1 729/4885CYP1A2 1329/4885 |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | ICAM1, VCAM1, CD14 | SMN1; SMN2 2867/4885ALDH1A1 443/4885CYP1A2 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.